Five-year echocardiographic follow-up after TAVI: structural and functional changes of a balloon-expandable prosthetic aortic valve
暂无分享,去创建一个
L. Fusini | M. Mapelli | M. Pepi | G. Tamborini | P. Gripari | M. Muratori | F. Alamanni | M. Agrifoglio | S. Ghulam Ali | A. Bartorelli | P. Trabattoni | M. Roberto | F. Fabbiocchi
[1] P. Serruys,et al. Five-year haemodynamic outcomes of the first-generation SAPIEN balloon-expandable transcatheter heart valve. , 2016, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.
[2] J. Zamorano,et al. Recommendations for the imaging assessment of prosthetic heart valves: a report from the European Association of Cardiovascular Imaging endorsed by the Chinese Society of Echocardiography, the Inter-American Society of Echocardiography, and the Brazilian Department of Cardiovascular Imaging. , 2016, European heart journal cardiovascular Imaging.
[3] P. Pibarot,et al. Incidence, Timing, and Predictors of Valve Hemodynamic Deterioration After Transcatheter Aortic Valve Replacement: Multicenter Registry. , 2016, Journal of the American College of Cardiology.
[4] Patricia A Pellikka,et al. Bioprosthetic Valve Thrombosis Versus Structural Failure: Clinical and Echocardiographic Predictors. , 2015, Journal of the American College of Cardiology.
[5] B. Griffin,et al. Early Bioprosthetic Valve Failure: Mechanistic Insights via Correlation between Echocardiographic and Operative Findings. , 2015, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.
[6] M. Mack,et al. 5-year outcomes of transcatheter aortic valve replacement or surgical aortic valve replacement for high surgical risk patients with aortic stenosis (PARTNER 1): a randomised controlled trial , 2015, The Lancet.
[7] Philippe Pibarot,et al. Assessment of paravalvular regurgitation following TAVR: a proposal of unifying grading scheme. , 2015, JACC. Cardiovascular imaging.
[8] T. Bourguignon,et al. Very long-term outcomes of the Carpentier-Edwards Perimount valve in aortic position. , 2015, The Annals of thoracic surgery.
[9] Jeroen J. Bax,et al. Effect of aortic regurgitation following transcatheter aortic valve implantation on outcomes. , 2015, The American journal of cardiology.
[10] M. Mack,et al. Paravalvular regurgitation after transcatheter aortic valve replacement with the Edwards sapien valve in the PARTNER trial: characterizing patients and impact on outcomes. , 2015, European heart journal.
[11] B. Iung,et al. Long-term outcome after transcatheter aortic valve implantation , 2015, Heart.
[12] J. Serfaty,et al. Early Structural Valve Deterioration of Mitroflow Aortic Bioprosthesis: Mode, Incidence, and Impact on Outcome in a Large Cohort of Patients , 2014, Circulation.
[13] Thoralf M Sundt,et al. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. , 2014, Journal of the American College of Cardiology.
[14] Thoralf M Sundt,et al. 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. , 2014, Circulation.
[15] Bart Meuris,et al. Antimineralization treatment and patient-prosthesis mismatch are major determinants of the onset and incidence of structural valve degeneration in bioprosthetic heart valves. , 2014, The Journal of thoracic and cardiovascular surgery.
[16] Susheel Kodali,et al. Two-Year Outcomes After Transcatheter or Surgical Aortic Valve Replacement , 2013 .
[17] Anson Cheung,et al. 5-year outcome after transcatheter aortic valve implantation. , 2013, Journal of the American College of Cardiology.
[18] M. Mack,et al. Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. , 2012, Journal of the American College of Cardiology.
[19] S. Pocock,et al. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. , 2010, The New England journal of medicine.
[20] E. Tay,et al. Transcatheter Aortic Valve Implantation: Durability of Clinical and Hemodynamic Outcomes Beyond 3 Years in a Large Patient Cohort , 2010, Circulation.
[21] Susan Armstrong,et al. Hancock II bioprosthesis for aortic valve replacement: the gold standard of bioprosthetic valves durability? , 2010, The Annals of thoracic surgery.
[22] S. Rahimtoola,et al. Choice of prosthetic heart valve in adults an update. , 2010, Journal of the American College of Cardiology.
[23] Bart Meuris,et al. Prosthesis-Patient Mismatch Predicts Structural Valve Degeneration in Bioprosthetic Heart Valves , 2010, Circulation.
[24] R. Suri. Aortic valve replacement with the Mitroflow pericardial bioprosthesis: Durability results up to 21 years , 2009 .
[25] Guidelines for reporting mortality and morbidity after cardiac valve interventions. , 2008, The Journal of thoracic and cardiovascular surgery.
[26] N. Smedira,et al. Failure modes of the Carpentier-Edwards pericardial bioprosthesis in the aortic position. , 2006, The Journal of heart valve disease.
[27] J E Okies,et al. Age and valve size effect on the long-term durability of the Carpentier-Edwards aortic pericardial bioprosthesis. , 2001, The Annals of thoracic surgery.